tbuckley/cabot-search huggingface dataset:
Hemodialysis in hepatorenal syndrome type 1 in alcoholic liver cirrhosis treated by continual terlipressin infusion in combination with albumin plasmaexpansion
Authors: P. Jarcuska, E. Veseliny, L. Bena, R. Roland, T. Hildebrand, B. Grejtovska, M. Hancova, A. Kovacova
Journal: Journal of Hepatology (2003)
The Sweet Contraceptive
Authors: Ralph Burbridge
Journal: JAMA (1975)

<h3>To the Editor.—</h3> I am writing about the editorial, "The Sweet Contraceptive" (231:392, 1975). Relative to the last paragraph of the editorial, if the groom used his thioglucose regularly, would it not be more appropriate to call him a "sugar non-daddy," rather than a "sugar daddy"?
Response to Comment on: Cherney and Sochett. Evolution of Renal Hyperfiltration and Arterial Stiffness From Adolescence Into Early Adulthood in Type 1 Diabetes. Diabetes Care 2011;34:1821–1826
Authors: David Z.I. Cherney, Etienne B. Sochett
Journal: Diabetes Care (2011)

We thank Drs. Lim and Tan for their interesting comments (1) regarding our article (2). First, we agree that the adrenomedullin (ADM) is an intriguing candidate that may be involved in the pathogenesis of diabetes-related vascular dysfunction as suggested by Lim et al. (3) and others (4). In terms of the relationship between hyperfiltration and ADM, we are only aware of experimental data by Hiragushi et al. (4). This group of investigators reported that streptozotocin-induced diabetic rats exhibited …
Abstract 4821: Circulating tumor cells: A key deliverable in oncology clinical trials
Authors: Chengsen Xue, Kasia E. Cortes, Dorina Hura, Melissa L. Baptiste, Paradiso Renato, Joanne Cuomo, Thomas W. Mc Closkey
Journal: Cancer Research (2014)

Abstract Circulating tumor cell (CTC) enumeration is a new pharmacodynamic biomarker developed from an emerging rare event technology showing prognostic potential for the management and monitoring of patients with colon, breast, and prostate cancer. As more evidence is gradually accumulating at multiple cancer institutes, CTC has the potential to become a surrogate marker for cancer prognosis. There are challenges in performing CTC testing, however this assay has the opportunity to become a key deliverable in oncology clinical trials. Our experience in the implementation of CTC testing in clinical trials over the past four years has led to recommendations for future CTC applications, including critical aspects such as sample accessioning and logistics, operational maintenance and method training, data collection and sufficient IT infrastructure to accommodate large data files in full scale trial operations. To have a successful trial using the CTC test as a monitored biomarker, the estimation of sample size for the clinical trial has to take into consideration the anticipated disqualification rate of collected samples. In our clinical trial experiences, 10% of samples submitted were disqualified for reasons ranging from insufficient sample volume to severe hemolysis. Sample logistics and transportation considerations are keys to successful sample management. Strict quality control (QC) measurements, a robust training program, effective data management, and proper maintenance of the CTC system are keys for delivering standardized results in a timely manner. Our results indicate that CTC testing can be effectively incorporated into large scale clinical trials and the data can be seamlessly integrated into the Laboratory Information Management System (LIMS). CTC results may offer clinically useful information about patients and their response to therapy. From a patient perspective, the CTC test only requires a tube of blood and is well suited to multiple sampling time points during a clinical trial. Citation Format: Chengsen Xue, Kasia E. Cortes, Dorina Hura, Melissa L. Baptiste, Paradiso Renato, Joanne Cuomo, Thomas W. Mc Closkey. Circulating tumor cells: A key deliverable in oncology clinical trials. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4821. doi:10.1158/1538-7445.AM2014-4821
Spinal cord injury in Rugby Union players
Authors: A. Savage
Journal: BMJ (1995)

ways, one would, strictly speaking, need hundreds of thousands of randomised trials to arrive at conclusive answers about the efficacy of this form of treatment.Clearly, this is not practical.The Centre for Complementary Health Studies is therefore planning a trial designed to answer the much broader question, "does homoeopathy work (regardless of remedy, dose, etc)?"I would be delighted to hear from potential participants in this multicentre study.EERNST
Studying mechanisms underlying shedding of endothelial membrane proteins could help patients at risk for myocardial infarction
Authors: A NEWBY
Journal: Cardiovascular Research (2005)

See article by Singh et al.  [8]  (pages 39–49) in this issue 

The single, most prevalent cause of premature death in the developed world is myocardial infarction, with more than 1 million occurrences each in Europe and the United States each year. For almost half of its victims, it is the first sign of coronary artery disease and, for a third, it is fatal. There is, therefore, an urgent need to define biomarkers to identify healthy individuals at high risk for myocardial infarction. These patients can then be targeted for aggressive risk factor reduction by established lifestyle and pharmacological approaches. There is also an emerging possibility of preventive coronary intervention, although this is yet to be validated in any clinical trial.

Atherosclerosis is a chronic inflammation of the vascular intima, which probably starts with endothelial dysfunction [1]. Oxidative stress impairs the action of endothelium-derived nitric oxide, antagonising its various roles as vasodilator, anti-platelet agent, and anti-inflammatory mediator [1]. Oxidative stress also upregulates a variety of transcription factors, including nuclear factor κB [2], which induce a complex of pro-inflammatory genes, including several chemokines and the endothelial leukocyte adhesion molecules, VCAM-1, ICAM-1, and P-selectin [3]. Upregulation of VCAM-1, in particular, seems to occur very early and to be a predisposing factor for atherosclerosis formation … 

*Tel.: +44 1179283582; fax: +44 1179283581. Email address: A.Newby{at}bristol.ac.uk
Forearm blood flow response to NO synthase inhibitor in essential hypertension
Authors: R. K Vubey
Journal: Cardiovascular Research (1994)

Forearm blood flow response to NO synthase inhibitor in essential hypertension Get access Raghvendra K Vubey Raghvendra K Vubey Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 28, Issue 12, December 1994, Pages 1873–1875, https://doi.org/10.1093/cvr/28.12.1873 Published: 01 December 1994
Frequency of Heterozygous and Homozygous Alphax_1-Antitrypsin Deficiencies in Patients with Pulmonary Emphysema.
Authors: Jack Lieberman
Journal: Annals of Internal Medicine (1969)

s1 May 1969Frequency of Heterozygous and Homozygous Alphax1-Antitrypsin Deficiencies in Patients with Pulmonary Emphysema.Jack Lieberman, M.D., F.A.C.P.Jack Lieberman, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-70-5-1098_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptHomozygous alpha1-antitrypsin deficiency is known to predispose to the development of pulmonary emphysema. Heterozygotes are not known to be so predisposed. In a study of the relatives of a homozygous proband, three heterozygous individuals had histories of chronic pulmonary disease. Because of this observation, 66 patients hospitalized with pulmonary emphysema were studied to determine the relative frequencies of homozygous and heterozygous deficiency. Trypsin inhibitory capacity (TIC) of serum was assayed spectrophotometrically with BAEE substrate.Approximately 25% of the patients hospitalized for pulmonary emphysema had a deficiency of antitrypsin activity. However, in patients less than 50 years of age the incidence... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Jack Lieberman, M.D., F.A.C.P.Affiliations: Duarte and Los Angeles, California PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAlpha-1-Antitrypsin 1 May 1969Volume 70, Issue 5Page: 1098-1098KeywordsEmphysemaPulmonary diseases ePublished: 1 December 2008 Issue Published: 1 May 1969 PDF downloadLoading ...
55 METABOLIC AND ANTI-INFLAMMATORY BENEFICIAL EFFECTS OF PIOGLITAZONE (PIO) TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND THEIR ASSOCIATIONS WITH HISTOLOGICAL IMPROVEMENT
Authors: A. Gastaldelli, B. Balas, R. Belfort, S. Harrison, J. Finch, D. Ciociaro, C. Darland, S. Schenker, K. Cusi
Journal: Journal of Hepatology (2009)
Home Discharge as a Performance Metric for Surgery
Authors: Joseph A. Hyder, Ronald E. Hirschberg, Louis L. Nguyen
Journal: JAMA Surgery (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Differential Dose-Response to Oral Xemilofiban After Antecedent Intravenous Abciximab
Authors: Dean J. Kereiakes, John Paul Runyon, Neal S. Kleiman, Nancy A. Higby, Linda C. Anderson, Gary Hantsbarger, Shawn McDonald, Robert J. Anders
Journal: Circulation (1996)

Background Placebo-controlled randomized trials of parenteral platelet glycoprotein (GP) IIb/IIIa receptor antagonists have demonstrated reduced ischemic complications of coronary angioplasty. Orally active GP IIb/IIIa blockers are being developed to allow more sustained receptor antagonism with potential for long-term secondary prevention. Sequential therapy with abciximab followed by an oral IIb/IIIa antagonist has not previously been reported. The clinical safety and pharmacodynamics of a sequential therapeutic strategy are unknown. Methods and Results Of 74 consecutive patients enrolled in a placebo-controlled, dose-ranging pharmacokinetic/pharmacodynamic study of xemilofiban, a new oral nonpeptide GP IIb/IIIa antagonist, after elective intracoronary stent placement, 17 patients received abciximab during stent deployment as a weight-adjusted intravenous bolus and 12-hour infusion at the discretion of the investigator. Ex vivo platelet aggregation in response to 20 μmol/L ADP and 4 μg/mL collagen was measured over time after the first dose of either xemilofiban (5, 10, 15, or 20 mg) or placebo (ticlopidine) administered 8 to 18 hours after termination of abciximab and again after 1 week of twice-daily oral administration of study drug. At baseline, patients who had received abciximab had lower platelet aggregation in response to both agonists ( P &lt;.001). A significant dose-response relationship to xemilofiban was observed. Patients who had received abciximab had lower ADP-induced ( P ≤.010) and collagen-induced ( P ≤.029) platelet aggregation after xemilofiban. This pharmacodynamic interaction was no longer evident at 1 week. No significant clinical bleeding events or blood product transfusions were observed in this trial. Conclusions Both the magnitude and the duration of pharmacodynamic response to xemilofiban were enhanced by prior abciximab treatment. The potentiated pharmacodynamic response was not evident after 1 week. This observation has implications for the safety and efficacy of sequential parenteral-oral GP IIb/IIIa blockade therapy and may be useful in deriving dose regimens for orally administered compounds.
Sézary Syndrome: A Model for Migration of T Lymphocytes to Skin
Authors: Miller Ra, Coleman Cn, Fawcett Hd, Hoppe Rt, McDougall Ir
Journal: New England Journal of Medicine (1980)

THE Sezary syndrome is characterized by generalized erythroderma, lymphadenopathy, splenomegaly, and the presence of abnormal mononuclear cells in skin infiltrates and peripheral blood.1 , 2 The neoplastic cells in this disorder have morphologic, immunologic, and functional similarities to thymus-derived (T) lymphocytes.3 4 5 The origin of the Sezary cell is unclear. Initially it was thought that Sezary cells originated in the skin.1 Autoradiography of skin lesions revealed a high number of labeled cells in the dermis as compared with a relatively low number in peripheral blood.6 Intravenous and intradermal injection of isotopes has also shown a greater labeling index for dermal Sezary cells.7 This . . .
PHYSICIANS CLAIMING EXEMPTION ON GROUNDS OF DEPENDENCY
Authors: R. S. Cone
Journal: JAMA (1918)

<h3>To the Editor:</h3> —It has been stated inThe Journalthat some local boards have refused to allow the claims of physicians to exemption or deferred classification on the ground that they are eligible for commission as officers in the Medical Reserve Corps. There has been no draft of doctors as such. This is not a draft of doctors. It is a civilian draft. All physicians under the age of 46 have been required to register just the same as all other citizens, have the same rights as all other citizens and are entitled to the same treatment that all other citizens receive. Does the fact that a man is a physician take away any of the constitutional rights which he enjoys in common with every other citizen? Every physician who can possibly see his way clear to do so should be proud to hold a commission in the Medical
Urea signaling in cultured murine inner medullary collecting duct (mIMCD3) cells involves protein kinase C, inositol 1,4,5-trisphosphate (IP3), and a putative receptor tyrosine kinase.
Authors: D M Cohen, S R Gullans, W W Chin
Journal: Journal of Clinical Investigation (1996)

Urea, in concentrations unique to the renal medulla, increases transcription and protein expression of several immediate-early genes (IEGs) including the zinc finger-containing transcription factor, Egr-1. In the present study, the proximal 1.2 kb of the murine Egr-1 5' -flanking sequence conferred urea-responsiveness to a heterologous luciferase reporter gene when transiently transfected into renal medullary mIMCD3 cells,and this effect was comparable with that of the extremely potent immediate-early gene inducer, O-tetradecanoylphorbol 13-acetate (TPA). Urea inducibility of Egr-1 expression was protein kinase C (PKC)-dependent because staurosporine and calphostin C abrogated the urea effect, and down-regulation of PHC through chronic TPa treatment inhibited both urea-inducible Egr-1 protein expression and gene transcription. In addition, hyperosmotic urea increased inositol 1,4,5-trisphosphate (IP3) release from mIMCD3 cells and induced tyrosine phosphorylation of the receptor tyrosine kinase-specific phospholipase C (PLC) isoform, PLC-gamma. Importantly, urea-inducible Egr-1 expression was strongly genistein-sensitive, to a much greater extent than the comparable TPA-inducible Egr-1 expression. These data suggest that urea-inducible Egr-1 expression is a consequence of sequential PLC-gamma activation, IP3 release, and PKC activation. Urea-inducible PLC-gamma activation, in conjunction with the genistein-sensitivity of urea-inducible Egr-1 expression suggest the possibility of a cell surface or cytoplasmic urea-sensing receptor tyrosine kinase.
The Increasing Incidence of Hepatocellular Carcinoma
Authors: Nedim Ince, Jack R. Wands
Journal: New England Journal of Medicine (1999)

Primary hepatocellular carcinoma, one of the most common tumors in the world today, is occurring with increasing frequency in the United States, as shown in the study by El-Serag and Mason in this issue of the Journal. 1 The most likely reason for this rising incidence is the spread of hepatitis virus infection in the population. Indeed, there is no better example of a tumor that is associated with persistent viral infection than hepatocellular carcinoma. Two viruses cause almost all these tumors: hepatitis B virus (HBV) and hepatitis C virus (HCV).The global distribution of hepatocellular carcinoma correlates with the geographic . . .
Long term exposure to hydrogen sulphide producing subacute encephalopathy in a child.
Authors: U B Gaitonde, R J Sellar, A E O'Hare
Journal: BMJ (1987)

described, but in our two patients there was no other obvious cause for this condition.At the time of their admission for myocardial infarction both patients had taken diamorphine, prochlorperazine, and glyceryl trinitrate; one patient (case 1) also took a few doses of frusemide and cyclopenthiazide, and the other required co-proxamol and buprenorphine intermittently over the first few days.None of these drugs, however, is known to cause peripheral neuropathy.Though we may have observed no more than a chance association, we suggest that patients who complain of weakness or lethargy after a myocardial infarct should undergo careful neurological examination.We thank Dr L D Blumhardt for arranging electrophysiological studies on these patients.
STATE BOARD OF HEALTH OF CONNECTICUT.
Authors: C. W. CHAMBERLAIN
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Discriminant Function Probability Model for Predicting Survival in Burned Patients
Authors: James A. McCoy
Journal: JAMA (1968)

Statistical data on 570 burn patients treated on the Plastic Surgery Service at the University of Texas Medical Branch were subjected to a multi-discriminant function analysis. After screening several items of information, the variables selected for study were age, extent of burn, and sex. The results were used to construct a "probability model" to predict the chance of survival in a simplified form which can easily be used by medical and trained paramedical personnel. This method offers a rapid and adequately accurate method for determining the probability of survival when the age, sex, and extent of burn are known in an individual patient.
Fewer hospitals in England should perform children's heart surgery
Authors: A. McGauran
Journal: BMJ (2011)

Public consultation starts later this month on four newly published options to reduce the number of hospitals in England providing children’s heart surgery from 11 to six or seven.

Safe and Sustainable —the NHS review into the future of children’s congenital heart services in England—put forward the proposals on 16 February. New quality standards are also proposed to ensure better care and survival rates.

While specialist surgical care would be centralised, the NHS would like more expert assessment and ongoing care services closer to families’ homes. The four month consultation launches on 28 February and a final decision will be made later this year.

All centres would need at least …
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma
Authors: Margarita Sala, Josep M. Llovet, Ramon Vilana, Lluís Bianchi, Manel Solé, Carmen Ayuso, Concepció Brú, Jordi Bruix
Journal: Hepatology (2004)

Outcome predictors in patients with hepatocellular carcinoma (HCC) who are treated with percutaneous ablation are ill defined, and it is unknown if successful therapy is associated with improved survival. In our study, 282 cirrhotic patients with early nonsurgical HCC were treated with percutaneous ablation during a 15–year period. Single tumors were seen in 244 patients, and 2 to 3 nodules were seen in 38 patients. Initial complete response was achieved in 192 patients and was independently related to the size of the main tumor ( P = .015) and tumor stage ( P = .0001) (≤2 cm, 96%; 2.1–3 cm, 78%; &gt;3 cm, 56%; 2–3 nodules, 46%). At the end of follow–up, 80 patients presented sustained complete response. The 1–, 3–, and 5–year survival rates were 87%, 51%, and 27%, respectively. The independent predictors of survival were Child–Turcotte–Pugh class ( P = .0001) and initial complete response ( P = .006). Child–Turcotte–Pugh class A patients with initial complete response achieved 42% survival at 5 years; this figure increased to 63% in patients with tumors 2 cm or smaller. In conclusion , our results demonstrate that initial complete response to percutaneous ablation is associated with an improved survival in both Child–Turcotte–Pugh class A and B patients with nonsurgical HCC. Accordingly, initial complete tumor necrosis should be considered a relevant therapeutic target irrespective of tumor size and liver function. (Hepatology 2004;40:1352-1360.)